CORRECTION: Sequenom's Q3 Revenues Drop 20 Percent as Net Loss Swells 43 Percent | GenomeWeb

This article has been corrected from an earlier version that said that Sequenom had "shelved" its SEQure Dx test following an investigation into mishandled data. The firm is continuing development of the test.

NEW YORK (GenomeWeb News) – Sequenom said after the market closed today that its third-quarter revenues dropped 20 percent while its net loss increased 43 percent.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.